ArticleJournal for immunotherapy of cancer2025

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.

Blessie E Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.